Abstract

The regulation of the necrotic death and its relevance in anticancer therapy are largely unknown. Here, we have investigated the proapoptotic and pronecrotic activities of two ubiquitin-proteasome system inhibitors: bortezomib and G5. The present study points out that the glioblastoma cell lines U87MG and T98G are useful models to study the susceptibility to apoptosis and necrosis in response to ubiquitin-proteasome system inhibitors. U87MG cells show resistance to apoptosis induced by bortezomib and G5, but they are more susceptible to necrosis induced by G5. Conversely, T98G cells are more susceptible to apoptosis induced by both inhibitors but show some resistance to G5-induced necrosis. No overt differences in the induction of Noxa and Mcl-1 or in the expression levels of other components of the apoptotic machinery were observed between U87MG and T98G cells. Instead, by comparing the transcriptional profiles of the two cell lines, we have found that the resistance to G5-induced necrosis could arise from differences in glutathione synthesis/utilization and in the microenvironment. In particular, collagen IV, which is highly expressed in T98G cells, and fibronectin, whose adhesive function is counteracted by tenascin-C in U87MG cells, can restrain the necrotic response to G5. Collectively, our results provide an initial characterization of the molecular signals governing cell death by necrosis in glioblastoma cell lines.

Highlights

  • Glioblastomas (GBM) are among the most lethal tumors

  • Dose-dependent studies showed that U87MG cells are more prone to die in response to G5 compared with T98G cells (Fig. 1A)

  • U87MG cells were more resistant to cell death (∼30% of dead cells after incubation with 10 μmol/L of bortezomib), whereas T98G cells were more sensitive (>80% of death under the same conditions)

Read more

Summary

Introduction

Grade IV GBMs (WHO grade 4) are highly recalcitrant to radiotherapies and chemotherapies, exhibiting robust angiogenesis, resistance to apoptosis, and propensity to necrosis. Isopeptidases are attractive alternative targets of the UPS for developing new antitumor therapies [5]. Isopeptidases can be generally subdivided into deubiquitinating enzymes and ubiquitin-like (Ubl) specific proteases, which, respectively, deconjugate ubiquitin or Ubl molecules, such as SUMO, NEDD8, or ISG15, from target proteins. These enzymes modulate several biological processes through the control of the lifetime, localization, and activity of ubiquitin or Ubl-modified proteins [6, 7]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.